Eisai Could Have Difficulty Ending Market Deal With Pfizer
This article was originally published in PharmAsia News
Executive Summary
Eisai's attempt to extricate itself from a marketing agreement with U.S.-based Pfizer for Eisai's Aricept (donepezil) for treating Alzheimer's disease may not be as easy as it thought. Eisai sought to end the deal after Pfizer announced it would take over another U.S. firm, Wyeth, but Pfizer is resisting the breakup. Eisai contends the merger with Wyeth violates Pfizer's contract with Eisai, so the contract has been nullified. At stake are huge sales commissions Eisai pays to Pfizer to market Eisai's best-selling drug. Eisai says it can do the marketing itself. (Click here for more - a subscription may be required